Market research
MRK.PA Merck & Co., Inc
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 261B
- P/E ratio
- 21.04
- Analyst target
- Not available
- Dividend yield
- 2.8%
- Beta
- 0.36
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- ISIN
- US58933Y1055
- Market cap
- 261B
- P/E ratio
- 21.04
- Analyst target
- Not available
- Dividend yield
- 2.8%
- Beta
- 0.36
About
About Merck & Co., Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MRK.PA discussion.
5 years, 5 months ago
Merck & Co., Inc is currently in a long term uptrend where the price is trading 1.1% above its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.
Merck & Co., Inc's total revenue rose by 5.4% to $13B since the same quarter in the previous year.
Its net income has dropped by 188.9% to $-2B since the same quarter in the previous year.
Finally, its free cash flow fell by 31.9% to $2B since the same quarter in the previous year.
Based on the above factors, Merck & Co., Inc gets an overall score of 3/5.